分子诊断合作与授权协议（2016-2025）

本报告全面深入分析了全球领先的生物製药公司签署的分子诊断合作与许可协议，让您能够以前所未有的方式了解这些协议。

本报告经过全面修订和更新，详细介绍了2016年至2025年间的分子诊断协议。

本报告深入分析了企业签订分子诊断协议的原因和方式。这些协议通常包含多个组成部分，从合作研发开始，逐步推进到成果的商业化。

本报告涵盖合作、开发、研究和授权等内容。

本报告包​​含自2016年以来公布的759项分子诊断协议的完整清单，其中包括可用的财务条款以及合约双方披露的实际分子诊断合作协议的线上记录连结。此外，在条件允许的情况下，记录还包括公司及其合作伙伴向美国证券交易委员会提交的合约文件。

本报告第一章概述了分子诊断领域的交易活动。

第一章概述了本报告。

第二章概述了自2016年以来分子诊断领域的交易活动。

第三章概述了自2016年以来主要的分子诊断交易，并依交易总额列出。

第四章提供了分子诊断领域交易活动最活跃的前25家公司的完整列表，并附有简要概述，以及分子诊断交易和公开合约文件的完整列表。

第五章对自2016年1月以来已完成或宣布的、有公开合约文件的分子诊断相关交易进行了全面深入的审查。

第六章对自2016年1月以来签署和公布的分子诊断合作协议进行了全面深入的回顾。本章以具体的分子诊断技术类型进行组织。

本报告也包含大量表格和图表，展示了自2016年以来分子诊断领域的交易趋势和活动。

此外，我们还提供了一个全面的协议目录，依公司名称（A-Z）、协议类型和治疗靶点进行分类。每个协议标题都透过网路连结指向线上协议记录，并在可用的情况下指向协议文件，方便用户根据需要轻鬆存取每个协议文件。

主要优势

"分子诊断合作与授权协议" 报告提供读者以下主要优势：

• 了解2016年以来的交易趋势
• 浏览分子诊断领域的合作与授权协议
• 基准分析 - 确定交易市场价值
• 财务条款 - 首付款、里程碑付款、特许权使用费
• 依公司（A-Z）、协议类型和治疗领域分类的合约目录
• 以价值排名的主要交易
• 最活跃的交易撮合者
• 识别每笔交易中的资产和合约条款
• 存取合约文件 - 深入了解交易结构
• 尽职调查 - 评估拟议交易条款对合作公司的适用性
• 节省数百小时的研究时间

范围

• "分子诊断合作与许可协议报告" 旨在帮助读者深入了解分子诊断的发展趋势以及全球主要生物製药公司正在签订的协议结构。

分子诊断合作与授权协议包括：

• 生物製药产业的分子诊断交易趋势
• 製药和生物技术公司分子诊断合约记录目录
• 依价值划分的主要分子诊断交易
• 最活跃的分子诊断许可协议
• 分子诊断合作与许可协议提供对现有交易记录的全面访问，包括合约文件（如有）。

分析合约有助于对以下内容进行尽职调查：

• 合约中具体授予或选择哪些权利？
• 合约实际上赋予合作伙伴哪些权利？
• 授予了哪些独家经营权？
• 交易的付款结构是怎么样的？
• 销售和付款如何审计？
• 合约期限是多久？
• 合约的关键条款是如何定义的？
• 知识产权（IPR）如何处理与归属？
• 谁负责商业化？
• 谁负责开发、供应和生产？
• 如何管理保密性和资讯揭露？
• 如何解决争议？
• 在什么情况下可以终止合约？
• 如果所有权发生变更，会发生什么事？
• 如何约定转让许可和分包条款？
• 贵公司要求哪些标准条款？
• 哪些标准条款会因交易对手和交易类型而异？
• 贵公司必须受哪个司法管辖区管辖？

目录

摘要整理

第一章：引言

第二章：分子诊断交易趋势

• 引言
• 历年分子诊断交易
• 最活跃的分子诊断经销商
• 以交易类型划分的分子诊断交易
• 依治疗领域划分的分子诊断交易
• 依行业划分的分子诊断交易
• 分子诊断交易条款
  • 分子诊断交易的关键价值策略
  • 分子诊断合约预付款
  • 分子诊断交易里程碑付款
  • 分子诊断特许权使用费率

章节第三章：分子诊断领域的关键交易

• 引言
• 顶级分子诊断交易价值策略

第四章：最活跃的分子诊断交易撮合者

• 引言
• 最活跃的分子诊断经销商
• 最活跃的分子诊断交易公司简介

第五章：分子诊断交易目录

• 引言
• 分子诊断交易目录

第六章：依技术类型划分的分子诊断交易

• 交易目录
• 依公司划分的分子诊断交易目录（亚利桑那州）
• 以交易类型划分的分子诊断交易目录
• 依分子诊断交易类型划分的交易目录依治疗领域划分的诊断交易
• 交易类型定义
• 关于研究公司
• 当前合作伙伴
• 当前协议
• 近期合作伙伴报告标题

Molecular Diagnostics Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the molecular diagnostics deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of molecular diagnostics deals from 2016 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter molecular diagnostics deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 759 molecular diagnostics deals announced since 2016 including financial terms where available including links to online deal records of actual molecular diagnostics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of molecular diagnostics dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in molecular diagnostics dealmaking since 2016.

Chapter 3 provides an overview of the leading molecular diagnostics deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in molecular diagnostics dealmaking with a brief summary followed by a comprehensive listing of molecular diagnostics deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of molecular diagnostics deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of molecular diagnostics partnering deals signed and announced since Jan 2016. The chapter is organized by specific molecular diagnostics technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in molecular diagnostics deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Molecular Diagnostics Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse molecular diagnostics collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Molecular Diagnostics Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of molecular diagnostics trends and structure of deals entered into by leading biopharma companies worldwide.

Molecular Diagnostics Collaboration and Licensing Deals includes:

• Trends in molecular diagnostics dealmaking in the biopharma industry
• Directory of molecular diagnostics deal records covering pharmaceutical and biotechnology
• The leading molecular diagnostics deals by value
• Most active molecular diagnostics licensing dealmakers
• Molecular Diagnostics Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in molecular diagnostics dealmaking

• 2.1. Introduction
• 2.2. Molecular diagnostics deals over the years
• 2.3. Most active molecular diagnostics dealmakers
• 2.4. Molecular diagnostics deals by deal type
• 2.5. Molecular diagnostics deals by therapy area
• 2.6. Molecular diagnostics deals by industry sector
• 2.7. Deal terms for molecular diagnostics deals
  • 2.7.1 Molecular diagnostics deals headline values
  • 2.7.2 Molecular diagnostics deal upfront payments
  • 2.7.3 Molecular diagnostics deal milestone payments
  • 2.7.4 Molecular diagnostics royalty rates

Chapter 3 - Leading molecular diagnostics deals

• 3.1. Introduction
• 3.2. Top molecular diagnostics deals by value

Chapter 4 - Most active molecular diagnostics dealmakers

• 4.1. Introduction
• 4.2. Most active molecular diagnostics dealmakers
• 4.3. Most active molecular diagnostics deals company profiles

Chapter 5 - Molecular diagnostics contracts dealmaking directory

• 5.1. Introduction
• 5.2. Molecular diagnostics contracts dealmaking directory

Chapter 6 - Molecular diagnostics dealmaking by technology type

• Deal directory
• Deal directory - Molecular diagnostics deals by company A-Z
• Deal directory - Molecular diagnostics deals by deal type
• Deal directory - Molecular diagnostics deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Molecular diagnostics deals since 2016
• Figure 2: Active molecular diagnostics dealmaking activity - 2016 - 2025
• Figure 3: Molecular diagnostics deals by deal type since 2016
• Figure 4: Molecular diagnostics deals by therapy area since 2016
• Figure 5: Molecular diagnostics deals by industry sector since 2016
• Figure 6: Molecular diagnostics deals with a headline value
• Figure 7: Molecular diagnostics deals with an upfront value
• Figure 8: Molecular diagnostics deals with a milestone value
• Figure 9: Molecular diagnostics deals with a royalty rate value
• Figure 10: Top molecular diagnostics deals by value since 2016
• Figure 11: Most active molecular diagnostics dealmakers 2016 - 2025
• Figure 12: Molecular diagnostics deals by technology type since 2016